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The use of quality-adjusted life years (QALYs) as a commensurable health outcome measure 
has been encouraged by health authorities in many countries in order to aid decisions on 
healthcare priorities. A key methodological challenge is to estimate the weights used for 
valuing health-related quality of life, i.e. the “Q” in QALY, based on people’s preferences. 
Such generic preference-based measures (GPBMs) comprise a descriptive system and a value 
set that assign a value to each health state description on a 0 to 1 scale.    
The objective of this thesis was to provide improved knowledge of the usefulness of GPBMs, 
with an emphasis on the most widely applied instrument, the EQ-5D. More specifically, the 
thesis aims to i) investigate into the degree of non-linear relationships across GPBMs and 
provide exchange rates that differ depending on disease severity (Paper 1); ii)  develop 
mapping algorithms from depression scales (DASS-21 and K10) onto the EQ-5D (Paper 2) 
and iii) explore the causal and effect nature of EQ-5D dimensions (Paper 3). The analysis are 
based on an international sample from the Multi Instrument Comparison (MIC) project. A 
total of 7933 participants aged 18 years and above were included and separated into a non-
diagnosed healthy group (n=1760) and seven disease groups (n=6173). 
In Paper 1, quantile regression was used to investigate the degree of non-linear relationships 
between GPBMs (EQ-5D, SF-6D, HUI, and 15D) at nine different quantiles. Furthermore, the 
health state utility scale was split into intervals with 0.2 successive utility decrements to 
compare the GPBMs across different disease severities. The ER was calculated as the mean 
utility difference between two utility intervals on one GPBM divided by the difference in 
mean utility on another GPBM. The result revealed significant non-linear relationships across 
all four GPBMs. The degrees of non-linearity differed, with a maximum degree of difference 




differed by disease severity: at the lower end of the health state utility scale, the ER from SF-
6D to EQ-5D was 2.19, while at the upper end it was 0.35. These results illustrate the 
inaccuracy of using linear functions as cross-walks between GPBMs and suggest that level-
specific exchange rates should be used when converting a change in utility on one GPBM 
onto a corresponding utility change on another GPBM.  
Paper 2 aimed to develop mapping algorithms from two widely used depression scales: the 
Depression Anxiety Stress Scales (DASS-21) and the Kessler Psychological Distress Scale 
(K10) onto the EQ-5D-5L. Eight country-specific value sets (England, the Netherlands, 
Spain, Canada, China, Japan, Korea, and Uruguay) were applied. Data was based on the 
depression subgroup (n=917) of the MIC study. Six regression models were employed, 
including ordinary least squares regression, generalized linear models, beta binomial (BB) 
regression, fractional regression model, the MM-estimator, and censored least absolute 
deviation. Three model performance criteria were calculated to select the optimal mapping 
function for each country-specific value set: root mean square error, mean absolute error, and 
adjusted-r2. Generally, the results revealed that the fractional regression model was preferred 
in predicting EQ-5D-5L utility values from both the DASS-21 and K10. The only exception 
was the Japanese value set, for which BB regression model performed best. The mapping 
algorithms can adequately predict EQ-5D-5L utility values from scores on the DASS-21 and 
K10. This enables disease-specific data from clinical studies to be applied to estimate 
outcomes in terms of QALYs for use in economic evaluations.  
Paper 3 aimed to develop a conceptual framework for causal and effect relationships among 
the five dimensions of the EQ-5D (mobility, self-care, usual activities, pain/discomfort, and 
anxiety/depression) based on theoretical models of HRQoL, and test this framework using 




anxiety/depression as causal indicators that drive a change in the effect indicators of 
activity/participation, mobility, self-care, and usual activities. Note that mobility has also an 
intermediate position between pain/discomfort and the other two effect dimensions (self-care 
and usual activities). Confirmatory tetrad analysis (CTA) and confirmatory factor analysis 
(CFA) were used to test this framework using the full sample from the MIC project 
(N=7933). CTA produced the best fit for a model specifying self-care and usual activities as 
effect indicators and pain/discomfort, anxiety/depression, and mobility as causal indicators. 
This was supported by CFA, which revealed a satisfactory fit to the data based on the 
comparative fit index=0.992, the Tucker-Lewis index =0.972, the root-mean square error of 
approximation =0.075 (90% CI 0.062-0.088), and the standardized root-mean square residual 
=0.012. The EQ-5D-5L appears to include both causal indicators (pain/discomfort and 
anxiety/depression) and effect indicators (self-care and usual activities). Although mobility 
played an intermediate role in our conceptual framework, the analysis suggested that it is 





The demand for healthcare service is growing continuously, and the healthcare sector has 
insufficient resources to meet these demands. Resources like staff, facilities, and equipment 
are limited, and decisions about which treatments to provide, for whom, where, and when are 
based on these resources [1]. Any one course of action will lead to fewer available resources 
for pursuing alternative services, so limited resources should be allocated in the best possible 
manner to produce the best health outcome. Therefore, evaluating the impact on both costs 
and health outcomes is a necessary part of choosing between competing services and 
interventions, or prioritizing different patients (i.e. rationing) [2]. 
In order to aid decision-makers in making efficient (i.e. value for money) and fair resource 
allocations, economic evaluations are required by government agencies such as the National 
Institute for Health and Care Excellence in the United Kingdom [3], the Norwegian 
Medicines Agency in Norway [4], and other similar agencies around the world [5,6]. While 
the overall purpose of economic evaluations is the comparative assessment of the costs and 
benefits of alternative healthcare interventions [7], the health consequences of an intervention 
are often less evident than the resource consequences. Since a health effect may be multi-
dimensional, and in such a case is uncertain and may change, the measurement of the benefits 
of healthcare interventions is a critical part of an economic evaluation [1].  
Different techniques of economic evaluation use different units to measure health benefits [7]. 
Indeed, in order to compare health interventions, the outcome must be measured on a 
common metric to identify the one that is the least costly per unit of outcome [1]. In a cost-
utility analysis, this common metric is the quality-adjusted life year (QALY), which is a 
generic measure of health gain that combines the effects of an intervention on quality of life 
(QoL) and quantity of life. This is achieved by multiplying quality, i.e. the desirability of a 
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health state in terms of health-related QoL (HRQoL) by the duration of that health state (e.g. 
in years) [8]. The difficult task is measuring the quality weight (or the Q) in QALY.  
There are a vast number of measures that have been developed to capture treatment effects as 
expressed by patients’ own experiences, often referred to as patient-reported outcome 
measures (PROMs) [9]. PROMs may comprise one or multiple dimensions of health, 
assessing symptom(s), functional and health status, HRQoL, or QoL [10]. PROMs allow 
individuals to report their own experience on various health dimensions using a descriptive 
system; they provide a numeric value of health, which can be used to assess the efficacy and 
efficiency of interventions from a patient perspective [11-13]. However, most PROMs are 
disease-specific, making them less relevant for comparison across patient groups with 
different diseases. For this purpose, a generic measure is required. Furthermore, to be 
commensurable, trade-offs between health dimensions must be made to indicate the relative 
importance that people place on these dimensions. These measures are referred to as generic 
preference-based measures (GPBMs). 
GPBMs have been developed to obtain the quality weights (also referred to as utility values) 
needed to calculate the QALY [14]. Utility values are derived from two components: a 
generic descriptive system that allows patients to report their health state and a pre-
determined value set that provides values for each health state produced by the descriptive 
system. The values reflect an average of individuals’ preferences for the health states, which 
are elicited using health state valuation techniques like standard gamble (SG), time trade-off 
(TTO), visual analogue scale (VAS), or discrete choice experiment (DCE) [15]. There are six 
primary GPBMs in use, including the EuroQoL 5 dimensional questionnaire (EQ-5D), the 
Short Form 6 Dimensional Questionnaire (SF-6D), the Health Utility Index Mark 2 or Mark 3 
(HUI2/3), the 15 Dimensional Questionnaire (15D), the Assessment of Quality of Life 
(AQoL), and the Self-Assessed Quality of Well-Being Scale (QWB-SA) [14]. These 
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instruments can be applied across a range of patient groups and health conditions. All GPBMs 
purport to measure the same construct, which is utility. Here, utility is understood as a 
preference-based health state value that is anchored at 1 (full health) and 0 (being dead). 
However, studies indicate major discrepancies in the health state values produced by the 
different GPBMs for the same respondents. This is because GPBMs differ considerably in 
terms of the content and size of the descriptive system they use, as well as in the 
methodologies used for eliciting preference weights [16,17]. Thus, the intended comparability 
of studies is problematic when different GPBMs have been applied to measure the Q in the 
QALY.  
The problem of incommensurability of studies using different GPBMs has led some 
reimbursement agencies to choose a single GPBM for consistency in utility values. For 
instance, the EQ-5D is preferred by reimbursement agencies in the United Kingdom and 
Norway [3,4] and is the most widely used GPBM. A review by Richardson et al. [18]  found 
that the EQ-5D was applied in 63% of studies that applied a GPBM during the period 2005 to 
2010, followed by the HUI-3 (9.8%), SF-6D (8.8%), and 15D (6.9%). Furthermore, the EQ-
5D has dominated in most countries, except for the HUI in Canada and 15D in Finland. 
Another review by Wisloff and colleagues confirmed the dominant position of EQ-5D by 
revealing its application in 77% of cost-utility analysis published in 2010 [19].  
Another problem is that clinical trials more often include a disease-specific measure (DSM) 
than a GPBM [20]. Since a DSM is incommensurable, one solution is to develop 
transformations (or exchange rates) that enable the estimation of utility data based on 
responses given on a DSM. However, even with available utility data, transformations are 
necessary to either estimate health state utility values for the GPBM preferred by a health 
authority, or to enable comparisons of health effects [21]. This procedure is commonly 
referred to as mapping or cross-walking [20,22], which is the main focus of this thesis. 
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Moreover, due to the central role of the EQ-5D as the preferred GPBM among health 
authorities and its widespread use in applied studies, this thesis will concentrate particularly 
on this GPBM and will focus mainly on the new 5-level version (EQ-5D-5L), which includes 
the application of recently developed country-specific value sets, making this thesis timely 
and highly relevant. 
Mapping helps to reconcile the differences in health effects measured by different GPBMs. 
However, for mapping to be valid, there are some caveats that need particular attention. 
Studies have indicated non-linear associations between different GPBMs, and between 
GPBMs and DSMs [20,22-24]. However, previous studies on mapping have mostly applied 
linear transformations [20,22]. This implies that linear transformations would produce biased 
estimates at some part of the scale, usually at the top and/or bottom end. Hence, if mapping is 
to improve the comparison of health effects produced by different GPBMs, the critical fact 
that the strength of the association across GPBMs has been shown to vary at different disease 
severity levels should not be ignored. More knowledge about the presence of non-linear 
relationships across GPBMs is important, since it would advocate the use of non-linear 
transformations that could better harmonize the magnitude of units across GPBMs at different 
severity levels. Thus, Paper 1 of this thesis is the first study to specifically investigate non-
linearity across GPBMs (EQ-5D-5L, SF-6D, HUI-3 and 15D) using a novel approach, 
quantile regression models (QRMs). QRMs allow researchers to investigate the effect of one 
measure across the whole distribution of another measure. Furthermore, Paper 1 explored 
exchange rates between GPBMs at different severity levels, which has not been previously 
done. This has important policy implications, particularly when decision-makers are 
comparing alternative programs whose QALY calculations are based on different GPBMs. 
Paper 2 focused on developing mapping algorithms from two DSMs, the Depression Anxiety 
and Stress Scales 21-items (DASS-21) and Kessler Psychological Distress Scale 
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(K10), which are widely used measures of depression. This disease group was selected for 
several reasons. First, depression is a prevalent condition across all age groups, peaking in 
older adulthood. Globally, depressive disorders have been increasing in the last decade [25], 
and they are the single largest contributor to non-fatal health loss. The condition is different in 
the sense that it might last for longer periods, or may reoccur, significantly impairing an 
individual’s ability to function at work or school or to cope with daily life [26]. Depression 
can range from mild to severe; at its most severe, it can lead to suicide. Secondly, mental 
health is receiving increasing health policy attention, which will raise the demand for 
comparative assessments of healthcare interventions that target this patient group. Lastly, as a 
psychologist, this disease group has been of prime personal interest, as was the goal of 
contributing knowledge about DSMs applied in mental health, and my interest in 
investigating mapping from mental health measures onto GPBMs. Furthermore, based on the 
knowledge from Paper 1, in addition to other commonly applied models in mapping studies, 
two novel regression models were applied to seek out optimal transformations: a fractional 
regression model (FRM) and a beta binomial (BB) regression model that both account for the 
non-linearity in the data.  
While Papers 1 and 2 in this thesis concentrate on mapping, Paper 3 is more conceptual and 
reflects on how different dimensions of health are interconnected. Based on recommended 
models for conceptualizing the relationships between dimensions of HRQoL, Paper 3 is the 
first study to develop and empirically test a conceptual framework for causal and effect 
indicators among the five dimensions of the EQ-5D-5L. More knowledge on the causal 
pattern provides a better conceptualization of the underlying structure of the EQ-5D-5L, and 
might provide a better understanding of the relative importance of the five health dimensions 
as reflected in the preference-based value sets, as well as give insights into how to extend the 
descriptive system. A relatively new approach, referred to as confirmatory tetrad analysis, 
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 Concepts and definition of terms 
While health and QoL are everyday concepts used by laypersons, HRQoL is a concept used 
more among researchers. Although these terms are conceptually different, they are often used 
interchangeably, which can create confusion about their meaning. There is no single 
definition for either of these terms and still a debate about how to define them [27,28]. To aid 
in the understanding of this thesis, a brief definition of each term is given below.   
2.1.1 Health  
The World Health Organization (WHO) broadly defined the term health in 1948 as “a state of 
complete physical, mental and social well-being and not merely the absence of disease or 
infirmity” [29]. This has remained a highly influential definition. Yet, others have left out the 
mention of social well-being, defining health as “an individual’s level of function”, where 
“optimum function” is judged in comparison to “society’s standard of physical and mental 
well-being” [30]. Other more recent definitions have emphasized social and personal 
resources, as well as physical capacity [31], putting more emphasis on the capacity to cope 
autonomously with life’s ever-changing physical, emotional, and social challenges [32].  
2.1.2 Quality of life  
QoL is a broad-ranging concept that covers all aspects of people’s lives [33]. Although there 
are several definitions [28], the WHO defined QoL as “individuals’ perception of their 
position in life in the context of the culture and value systems in which they live and in 
relation to their goals, expectations, standards and concerns. It is a broad ranging concept 
affected in a complex way by the persons’ physical health, psychological state, level of 
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independence, social relationships, personal beliefs and their relationship to salient futures of 
their environment” [34]. 
2.1.3 Health-related quality of life  
The term HRQoL first appeared in the literature on health status measures in which HRQoL 
was used in the discussion of QALY as a measure of the value of 1 year of full health [28]. 
Thereafter, the use of HRQoL spread and refers to QoL when considered in the context of 
health and disease [35]. Thus, the term distinguishes the effects of illness and treatment from 
aspects of life that are beyond health care, e.g. political, societal, or cultural circumstances 
[36]. HRQoL is a dynamic multi-dimensional concept [37] and can be defined as “how well a 
person functions in her life and her perceived well-being in physical, mental, and social 
domains of health” [38]. Functioning refers to observable behaviors such as an individual’s 
ability to perform pre-defined activities, including the ability to interact with family and 
friends, and to participate in one’s work or studies [38,39], while well-being refers to the 
individual's internal subjective perceptions and feelings [38]. Accordingly, HRQoL goes 
beyond direct measures of health and focuses on the consequences of health status on QoL 
[35,36]. Another definition focuses on the value of health. Here HRQOL can refer to “the 
value assigned to different health states”, and these values, or utilities, are on a 0-1 dead-
healthy scale needed for QALY estimation, where values less than 1 indicate the loss of QoL 
or living in ill health [28]. Thus, as stated by Karimi and Brazier [28], if respondents’ 
preferences for health states reflect the impact of health on QoL, and they are able to estimate 
that impact correctly, then the utility of health states could be referred to as HRQoL. 
Although defining HRQoL has proven challenging, and several definitions have been 
proposed in the literature [40-43], generally there is a consensus that HRQoL is a multi-
dimensional concept that at least includes physical, mental, and social dimensions [36].  
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 Health-related quality of life measures 
2.2.1 Types of health-related quality of life measures 
The field of HRQOL assessment has become more sophisticated and methodologically 
rigorous [44], and there is a wide range of measures available [45,46]. These measures can be 
broadly divided into disease-specific versus generic. The vast majority are disease-specific, 
which measure how patients perceive the impact of a certain disease or health condition. 
Thus, the content of a DSM should be relevant for patients suffering from that health 
problem. Since all or most of the content comprising such a measure is relevant for the 
patients under study, the measure is generally thought to have a greater degree of precision to 
detect differences in severity and important changes over time [47]. The disadvantage of 
DSMs is the fundamental problem of comparability of outcomes of different treatments 
across patients groups with different health problems and diagnoses. Furthermore, DSMs may 
miss the impact of unanticipated problems related to the disease or side effects of treatments, 
as well as the impact of possible comorbidities [47].   
Generic measures assess a broad range of different health aspects across all types of morbidity 
and are often applicable to the general population [46]. These measures allow for comparison 
of scores across patients with various diseases or against the general population. Generic 
HRQoL measures can further be divided into non-preference-based and preference-based 
measures [14], also referred to as psychometric profiles or utility measures [48]. The most 
widely used non-preference-based measure in clinical trials is the Medical Outcomes Study 
36-item Short Form (SF-36) [49,50]. SF-36 provides a profile or description for assessing a 
patient’s health across eight different dimensions, i.e. physical functioning, social functioning, 
role limitations-physical, role limitations-emotional, bodily pain, vitality, mental health, and 
general health. The profile scores for each dimension indicate performance relative to both the 
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maximal and minimal level and, if calibrated to a population standard, the degree of health 
impairment in comparison to a population of interest [48]. However, although it is not 
uncommon in the literature [51], combining the dimensions of the SF-36 into an overall score, 
or total score, to measure health changes is not advisable, as it could lead to misinterpretation 
of any change [51]. Additionally, non-preference-based measures are not commensurable 
with lifetime gains. As a result, for health economic evaluations, i.e. cost-utility analyses, a 
preference-based HRQoL measure is essential to produce a cardinal index of health on a 0-1 
dead-healthy scale, where changes on this quality scale are commensurable with changes on 
the quantity of life scale.  
 Generic preference-based measures 
In health economic evaluations, it is essential to make healthcare programs comparable in 
terms of their cost-effectiveness. Effectiveness in producing health outcomes is measured by 
the QALY, and quality adjustment in the QALY needs to be measured in a way that 
systematically indicates the significance of various health effects in terms of HRQoL [8]. In 
this context, HRQoL is measured using a GPBM, also referred to as a multi-attribute utility 
instrument [15] or health state utility instrument [52]. Hereafter the term GPBM is used when 
referring to generic preference-based HRQoL measures in this thesis [1,7]. A GPBM consists 
of a descriptive system and a value set that assigns preference weights, or utility values, to 
each health state produced by the descriptive system. 
2.3.1 Descriptive systems 
There are six GPBMs described in the literature, and most provide more than one version 
[14]. These include the EQ-5D (EQ-5D-3L and EQ-5D-5L) [53,54], the SF-6D, derived from 
either the SF-12 or SF-36 [55,56], the HUI-2/HUI-3 [57,58], the 15D [59], the QWB-SA [60] 
and AQoL (AQoL-4D/AQoL-6D/AQOL-7D/AQoL-8D) [61-64]. They differ in terms of 
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descriptive systems, with a differing number of items/dimensions. Some dimensions are 
unique to one measure, while similar dimensions include different items, and there may be a 
different number of severity levels for each item/dimension. Indeed, the number of items and 
dimensions vary considerably (Table 1): some measures include one item per dimension (e.g. 
EQ-5D and HUI-3), while others include several items (e.g. SF-6D and AQoL-8D). Since 
each GPBM includes a different number of dimensions, and the level of the dimensions are 
different across descriptive systems, each GPBM defines a different number of health states. 
Due to the dominant position of the EQ-5D, and since it is the primary focus in this thesis, it 
will be described in more detail to exemplify how an individual’s health state is defined. 
Other measures included in this thesis are described in the appendix.  
The EQ-5D is the shortest GPBM and includes five items/dimensions: mobility, self-care, 
usual activities, pain/discomfort, and anxiety/depression. In the original version (EQ-5D-3L), 
which was developed more than 25 years ago, each item had three levels, thus it defined 243 
health states (35) [53]. More recently, a five-level version, the EQ-5D-5L, was developed [54] 
to respond to concerns about the insensitivity of the EQ-5D-3L. In the EQ-5D-5L, two more 
response levels were added to each dimension to reduce potential ceiling effects and improve 
reliability and sensitivity [54,65]: the level ‘slight problems’ was added in between “no 
problems” and “moderate problems”, and the option “severe problems” was added in between 
“moderate problems” and “unable to/extreme problems” (Box 1). When responding to the 
EQ-5D-5L, the health state is determined by taking one level from each dimension. That is, 
the best possible health state (or full health) is defined as a response of no problem (level 1) 
on every dimension (i.e. 11111), while the worst possible health state is described by unable 
to/extreme problems (level 5) on every dimension (i.e. 55555). When including every other 
health state combination between best and worst health states, the EQ-5D-5L defines a total  
of 3125 (or 55) health states. Thus, the more dimensions and levels included in a GPBM   
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 Table 1. Descriptive systems of GPBMs  
 a The relative use of GPBMs was based on 1682 studies published between 2005 and 2010. Of these, 15% were 
primarily concerned with economic evaluations (for details, see Richardson et al. [18]). 
bThe relative use of GPBMs was based on 370 studies published in 2010 (for details, see  Wisloff et al. [19] 
cSF-6D derived from SF-36. 
dThe three multi-response items of the QWB-SA - mobility, social activity, and physical activity - define 47 health 
states, and the remaining symptom/problem groups define 898 health states.  
eAQoL-8D has 35 items comprising of eight dimensions. 
 
descriptive system, the more health states can be defined, e.g. 15D comprises 15 dimensions 
with 5 levels each, defining more than 30 (or 515) billion health states. After respondents 
describe their health state, the next step is to apply an algorithm that assigns a preference  






Relative use (%) 
Study 1a Study 2b 
EQ-5D-
5L/3L 
(5) Mobility,  self-care, usual 
activities, pain/discomfort, and 
anxiety/depression  




(6) Energy, mental health, pain, 
physical functioning, role 
limitation, and social 
functioning 
11 4 to 6 18,000 8.8 11.5 
HUI-2 
(7) Sensation, mobility, 
emotion, cognition, self-care, 
pain, and fertility  





(8) Vision, hearing, speech, 
ambulation, dexterity, emotion, 
cognition, and pain 
8 5 to 6 972,000 9.8 
15D 
(15) Mobility, vision, hearing, 
breathing, sleeping, eating, 
speech, elimination, usual 
activities, mental function, 
discomfort/symptoms, 
depression, distress, vitality, 
and sexual activity 
15 5 31 billion 6.9 4.4 
QWB-SAd 
(4) Mobility, physical activity, 
social functioning; 68 
symptoms/problems 
71 2 to 3 945 2.4 1.8 
AQoLe 
(8) Coping, happiness, 
independent living, mental 
health, pain, relationship, self-
worth, and senses 





weight, or an index value, to each health state. These algorithms are developed based on 
methods for measuring preferences on a 0-1 scale, where 0 equals being dead and 1 equals 
full health. However, negative values are also possible and indicate health states that are 
considered worse than being dead. There are four valuation techniques commonly referred to 
in the literature for valuing health states, namely the VAS, SG, TTO, and more recently, the 
DCE (Table 2). 
Box 1: EQ-5D-5L descriptive system 
Select the answer under each heading below that best describes your own health state today 
a) Mobility 
I have no problem in walking about   
I have slight problems in walking about   
I have moderate problems in walking about   
I have severe problems in walking about   
I am unable to walk about   
b) Self-care 
I have no problems washing or dressing myself 
  
I have slight problems  washing or dressing myself   
I have moderate problems  washing or dressing myself   
I have severe problems  washing or dressing myself   
I am unable to wash or dress myself. 
  
c) Usual activities (e.g. work, study, housework, family or leisure activities) 
I have no problems doing my usual activities   
I have slight problems doing my usual activities   
I have moderate problems doing my usual activities   
I have severe problems doing my usual activities   
I am unable to do my usual activities   
d) Pain/discomfort 
I have no pain or discomfort 
  
I have slight pain or discomfort 
  
I have moderate pain or discomfort 
  
I have severe pain or discomfort 
  
I have extreme pain or discomfort 
  
e) Anxiety/depression  
I am not anxious or depressed   
I am slightly anxious or depressed   
I am moderately anxious or depressed   
I am severely anxious or depressed   
I am extremely anxious or depressed   
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Table 2. Valuation techniques of GPBMs   
a The minimum score for the UK value set (for details, see Dolan [66]).  
b The minimum score for the English value set (for details, see Devlin et al. [67])  
c  The MAU theory reduces the valuation task by making simplifying assumptions about the relationship between 
dimensions (for details, see Brazier et al. [1]). 
dAQoL-8D employs both MAU theory and statistical modelling to estimate a function for valuing health states.  
 
 
2.3.2 Valuation techniques 
Visual analogue scale  
VAS is a line (usually presented vertically) with well-defined endpoints, on which the value 
0, located at the lower end, indicates the worst imaginable health or being dead, and 100, 
located at the upper end, indicates the best imaginable or full health (Figure 1). Since 
respondents are asked to judge, value, or feel where their health state is located on the scale, 
the VAS is sometimes referred to as a feeling thermometer. The VAS is considered to have 
interval properties, where the distance between intervals reflects a respondent’s preference for 
the different health states being measured. Thus, the difference in health from 10 to 20 should 
be equal to the differences between 60 and 70.  
GPBM Valuation technique Forms of algorithm Scoring formula Minimum score 
EQ-5Da TTO, DCE,  Statistical  Additive 3L: -0.594a 
5L: -0.281b 
SF-6D SG Statistical  Additive 0.301 
HUI-3 SG, VAS MAUc  Multiplicative -0.36 
15D VAS MAU  Additive 0.00 
QWB-SA VAS MAU  Additive 0.00 






Figure 1. Example of a VAS  
 
Standard gamble  
SG is the classic method for measuring preferences, based directly on the axioms of the von 
Neumann and Morgan utility theory (86). The utility for a health state is the amount of risk, in 
terms of probability, the respondent is willing to accept for not being in the valued health 
state. The preference for the health state is the point where the respondent becomes indifferent 
between two treatment outcomes: one which involves uncertainty with two possible outcomes 




Figure 2. Valuation of health states with the SG 
 
The basic format for the SG in the case of chronic health states that are preferred to being 
dead is illustrated in Figure 2a. Alternative 1 has two possible outcomes: either the patient 
returns to full health and lives for additional t years (with probability p) or the patient dies 
immediately (with probability 1-p). Alternative 2 is a certain outcome of chronic state hi for 
life (t years). The probability p of successful treatment (returning to full health) varies until 
the individual is indifferent between the risky option (alternative 1) and the certain outcome 
(alternative 2), at which the value of hi is equal to p. That is: 
hi=p* full health + (1-p) dead dead =>  hi=p, where full health=1 and dead=0 
In the case of chronic health states considered worse than being dead, the SG can be slightly 
modified by making the certain outcome (alternative 2) dead, and making the risky option 
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(alternative 1) a gamble between full health after treatment (probability p) or remaining in the 
chronic health state (hi) for life (probability 1-p) (86). As before, probability p varies until the 
respondent becomes indifferent between the certain outcome of death and the risky option, at 
which the utility for hi=-p/ (1-p) (Figure 2b). In the literature, the SG is often regarded as the 
preferred method due its theoretical basis and the fact that one of its features is decision-
making under uncertainty [1]. Indeed, since medical decisions usually involve uncertainty, the 
SG is often labeled the gold standard due to its uncertain nature [7]. However, it has been 
argued that the type of uncertainty in the SG is not comparable with the various uncertainties 
in medical decisions, making this feature less relevant [68]. Furthermore, individuals often 
have a hard time understanding probabilities.  
Time trade-off  
Torrance et al. [69] introduced the TTO method to provide a simpler method than the SG. 
Both methods derive preferences implicitly based on the respondent’s choices in given 
situations. However, while the SG is risk-sensitive due to uncertainty in the outcome, the 
TTO is riskless. The basic format for the TTO in the case of chronic health states that are 
preferred to being dead is illustrated in Figure 3a. The respondents are offered two 
alternatives: alternative 1 is health state i for time t (usually 10 years) followed by death; 
alternative 2 is healthy for time x (x < t) followed by death. If the respondent is willing to 
trade life expectancy, time x is varied until the respondent is indifferent between the two 
alternatives, at which point the preference value for chronic state i is:  hi=x/t.  
For chronic health states considered worse than being dead, the TTO can be altered so that 
respondents can choose between immediate death (alternative 1), or health state hi for a period 
of time (y), followed by x years in full health where x+y=t. By varying time (x) until the 
respondent is indifferent between the two alternatives, the value of hi can then be given as: hi 















(b) Lead time TTO considered worse than death (i.e. values < 0) 
 
Alt. 1 (t-years) 
 f years (t-f) 
Alt. 2 (g-years)  
  
                                           g years 
Figure 3. Valuation of health states with (a) conventional TTO and (b)  
lead-time TTO   
 
compensate for the time spent in hi. The formula translating TTO responses to health state 
values considered worse than being dead produces a scale that ranges from minus infinity to 
1, where a greater weight is given to negative values, which has implications for economic 
evaluations [52,70,71]. While this has been resolved by assigning a preference value of -1 to 
the worst possible health state among those health states considered worse than being dead 




















A solution has recently been proposed to handle values for states considered worse than 
being dead, referred to as lead–time TTO. This method was introduced as an alternative to the 
conventional TTO and is applicable for health states considered either better or worse than 
being dead [70]. This approach involves adding additional time spent in full health before the 
period spent in the impaired health state (alternative 1), as well as to the period spent in full 
health or death (alternative 2) [1]. That is, alternative 1 is full health for f years (lead-time), 
then state hi for t-f years; while alternative 2 is full health for g years (lead-time), where g is 
larger than f for health states considered to be better than being dead, and less than f for 
states considered to be worse than being dead. The latter is illustrated in Figure 2b. State hi is 
then calculated as hi=(g-f)/(t-f). Health states considered better than being dead receive a 
positive value and states considered worse than being dead receive a negative value [73].  
Since studies have shown the lead-time TTO exercise has severe framing effects, and it is 
clearly difficult for respondent to perform the task [70,71,74], a composite TTO was 
introduced as a compromise between the conventional TTO and lead-time TTO [75]. Thus, 
the composite TTO considers the conventional TTO for health states considered better than 
being dead and the lead-time TTO for states below zero. The EuroQol group adopted this 
approach for the valuation of the EQ-5D-5L, which improved the means of eliciting values 
worse than being dead and resolved the problem of assigning an arbitrary value to the worst 
possible health state for rescaling the conventional TTO [76]. While the TTO was developed 
to be a simpler alternative to SG, there is still a concern that it is cognitively demanding for 
some populations, leading to several inconsistencies and subsequent exclusions that limit the 
representativeness of the values produced [77,78].  
Discrete choice experiment 
Another method for eliciting preferences is the DCE, which has been promoted as a simpler 




Which is better, state A or B? 
 moderate problems in walking about  slight problems in walking about 
 no problems washing and dressing myself  no problems washing and dressing myself 
 moderate problems doing my usual activities  moderate problems doing my usual activities 
 slight pain or discomfort  extreme pain or discomfort 
 not anxious or depressed  severely anxious or depressed 
A B 
 
Figure 4. Example of two profiles from the EQ-5D-5L descriptive system provided in a 
DCE task 
 
provided with two or more profiles, and they choose the most or least preferred, as 
exemplified in Figure 4. Different scenarios are constructed based on a descriptive system 
made up of levels of a limited number of important attributes [80].  
Respondents simply indicate that option A is preferred to option B, without the iterative 
process used in the TTO to find the point of indifference between the two options [81]. The 
relative preferences of one health state over another are commonly provided by the 
conditional logit model [79]. Since the utility scale for DCE data from this model is not 
anchored to the 0-1 dead-healthy scale, it cannot be directly incorporated for calculating 
QALY. The EuroQoL valuation protocol includes DCE in addition to a TTO task and 
combines data from both techniques into a single modelling framework, referred to as the 
hybrid model [67,82]. The coefficient from both models are connected via a link function to 
account for the differences between the scales [83]. The hybrid model maximizes the use of 
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the available data from a valuation study using the EuroQoL valuation protocol [82]. 
However, there are promising approaches referred to as DCETTO that link health states to 
normal health and death within a DCE by including ‘survival duration’ as an attribute 
[67,81,84,85].  
Comparison of valuation techniques 
Different valuation techniques normally produce different values for the same health states. 
The majority of studies suggest that the VAS generally generates lower values than SG and 
TTO [86]. However, it has been shown that milder health states generate lower SG values 
than the VAS, with a crossover point at around 0.8 on a 0-1 dead-healthy scale [87].  While 
the relationship is less consistent for studies reporting VAS and TTO results, VAS usually 
generates lower values [86,88]. Studies have also indicated inconsistent results for the 
relationship between the SG and TTO. As the SG involves uncertainty, it has been suggested 
that it produces higher values than the TTO due to risk aversion. This is a key difference 
between the choice-based techniques. Nevertheless, one study suggested that the TTO 
produces higher values for milder health states, with a crossover point around 0.4 when 
compared to the VAS [87]. Additional sources of bias that may lead to differences in SG and 
TTO values include: probability weighting (upward bias in SG values), utility curvature 
(downward bias in TTO values), loss aversion (upward bias in both TTO and SG values), and 
scale compatibility (upward bias in TTO values and ambiguous bias in SG values, 
respectively) [1,89]. Probability weighting does not affect TTO values since these are elicited 
under the condition of certainty, while the SG is not affected by utility curvature since no 
restrictions are imposed on the utility function for the duration of the health state. Considering 
the relationship between the DCE and TTO, one study showed that the DCE assigns relatively 
higher values to milder health states and lower values to poorer health states [90].  
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2.3.3 Generic preference-based measures compared 
The majority of studies comparing GPBMs suggest a low level of agreement [18]. It has 
generally been indicated that health state utility values are not equivalent across measures, 
and comparisons “warrant caution” [23,91]. While mean scores have been found to be similar, 
they often mask major differences across the distribution [14,23,92]. The differences across 
measures can be explained in part by differing descriptive systems, valuation techniques, and 
the model used to create the formula or algorithm used to extrapolate results. Studies have 
suggested that the dominant reason for these differences is the lack of overlap in the 
descriptive systems [16,93]. Similarly, the scale effect that arises from the use of different 
valuation techniques is also an important source of variation. One approach to increase 
comparability across GPBMs is to develop mapping algorithms that can predict health state 
utility values from one GPBM based on values from another GPBM.  
 Transformations 
2.4.1 The concept of mapping 
Mapping is conducted to link outcome data collected in clinical trials or observational studies 
to a GPBM to obtain utility values. Key clinical trials are often designed for purposes other 
than economic evaluations, hence a GPBM is not necessarily included as a PROM. In the 
scenario of missing utility data, mapping or “cross-walking” is one solution to enable cost-
effectiveness analyses [94]. This approach enables the transformation of scores from a source 
measure, usually a condition-specific measure, into health state utilities, by applying a pre-
existing mapping algorithm. Generally, mapping algorithms are developed by distributing 
both measures of interest to the same respondents, then applying statistical methods to predict 
health state utilities from scores on a source measure. Subsequently, the mapping algorithm 
can be applied to transform condition-specific data from clinical trials into health state utility 
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values [1,22]. Here I focus on mapping onto the EQ-5D for two reasons. First, it is the most 
widely applied GPBM in mapping studies, and in cost-utility analysis in general; second, the 
EQ-5D is of main interest in all three papers in this thesis.   
2.4.2 The literature on mapping studies: the case of the EQ-5D  
The practice of mapping onto the EQ-5D from other measures of health outcome is increasing 
in number, especially after the UK National Institute for Health and Care Excellence endorsed 
this practice when EQ-5D utilities are unavailable [22]. A literature search performed on 26 
October 2017 in the EMBRACE and HERC databases identified a total of 150 studies that 
mapped onto the EQ-5D. For detailed information on the inclusion/exclusion criteria for the 
literature search, see Dakin [22]. Although the two databases searched identified mostly the 
same studies, 18 studies found in EMBRACE were not found in HERC. This is because these 
studies were published after the HERC database was last updated in May of 2016. Of the 150 
studies identified, 141 studies mapped onto the EQ-5D-3L, while nine studies mapped onto 
the EQ-5D-5L [24,95-102]. Of the nine 5L mapping studies, eight mapped from DSMs, while 
one mapped from other GPBMs [24]. Five of the EQ-5D-5L mapping studies applied the 
interim cross-walk value set [103], and three applied directly-elicited value sets. Of the latter 
three studies, two applied the English and Dutch value sets [98,99], while one applied the 
Japanese value set [96]. The source measures in these studies included DSMs related to 
cancer and epilepsy. A recent review by Dakin et al. [104] supports the findings of the 
literature search in the current thesis. While the studies that mapped onto EQ-5D-3L did 
include mental health measures, none of those that mapped onto EQ-5D-5L used directly-
elicited value sets. 
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 Causal and effect indicators among health-related quality of life 
dimensions 
HRQoL measures comprise items that relate to various aspects of symptoms and functioning. 
Previous research has attempted to classify the items included in these measures as causal or 
effect indicators of HRQoL [105]. Effect indicators (also referred to as reflective indicators) 
can be seen as manifestations of an underlying construct, in which indicators are assumed to 
be drawn from an infinite pool of homogeneous indicators representing that construct, making 
them largely interchangeable. Thus, the causal flow is from the construct to the indicators, 
implying that any change in the construct will have an effect on the indicators. Conversely, 
causal indicators (also referred to as formative indicators) drive a change in the construct. As 
exemplified by Bollen and Lennox [106], life stress can be indicated by observed variables 
like job loss, divorce, recent bodily injury, or death in the family. These indicators are clearly 
causal indicators since the causal flow is from the indicators to the construct i.e. a change in 
life stress does not necessarily imply that a simultaneous change will occur across all causal 
indicators.  
There is evidence to suggest that symptoms have a strong causal component that drives a 
change in other items [107,108]. The research into the causal nature of various HRQoL items 
has been limited to the cancer-specific measure, the European Organization for Research and 
Treatment of Cancer Quality‐of‐Life questionnaire (EORTC QLQ-C30), which has been 
investigated in three studies. Fayers and colleagues found strong evidence that physiological 
symptom items (e.g. nausea, memory problems, shortness of breath) were causal indicators, 
while items such as poor concentration, irritability, and feeling tense were likely to be effect 
indicators [107]. Boehmer and Luszczynska [108] identified both causal indicators 
(symptoms like fatigue and pain) and effect indicators (e.g. physical, role, cognitive, social, 
and emotional functioning). They suggested that physical functioning and pain might be 
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intermediate indicators. Using eight EORTC QLQ-C30 items, Bollen et al. [109] concluded 
that symptom items (e.g. shortness of breath, problems sleeping, lack of appetite) should be 
treated as causal indicators, while global health status and QoL should be treated as effect 
indicators. So far, no studies have investigated the classification of causal and effect 





The general objective of this thesis was to provide a better understanding and knowledge of 
GPBMs commonly applied in economic evaluations. The research questions addressed in the 
three papers included in this thesis are:      
Paper 1: To investigate the degree of non-linear relationships across the four most widely 
used GPBMs (EQ-5D-5L, SF-6D, HUI-3, and 15D). We also provided exchange rates 
(coefficients) between GPBMs that differ depending on which intervals of the scales are 
considered. 
Paper 2 had several aims: First, to replace existing mapping algorithms between the 
depression-specific measures DASS-21 and K10, and the EQ-5D-5L, which were developed 
using an interim EQ-5D-5L cross-walk value set based on the EQ-5D-3L value set for the 
UK. Second, to investigate if the mapping algorithms differed across different, directly 
elicited, country-specific health state preferences, including four Western countries (England, 
the Netherlands, Spain, Canada), three Asian countries (China, Japan, Korea) and one South 
American country (Uruguay). Third, to investigate the relative merit of six regression models.  
Paper 3: To develop a conceptual framework for causal and effect relationships among the 
five dimensions of the EQ-5D-5L based on theoretical models of HRQoL, and to test this 




3 Materials and methods 
 Data 
This thesis is based on a unique international dataset from the Multi Instrument Comparison 
(MIC) project, which is the world’s largest survey comparing GPBMs. The project was 
established in response to the growing evidence showing that different GPBMs produced 
different values for the same respondents and measured different constructs, although all 
GPBMs purport to measure the same construct: health state utility. While Richardson et al. 
[18] identified 392 pair-wise comparisons of GPBMs, only four studies included five 
GPBMs. Thus, the lack of thorough comparisons and comparative data was the principal 
motivation for the MIC project. The main aim was to document differences and the extent of 
the problem using a large database. The MIC project is the first study identified in the 
literature to include all six GPBMs, as well as eight DSMs and three subjective well-being 
measures. The MIC project is also unique in that it includes respondents from six countries 
(i.e. Australia, Canada, Germany, Norway, the UK, and the US), comprising a total of seven 
disease groups (i.e. asthma, arthritis, cancer, depression, diabetes, hearing loss, and heart 
disease) and an undiagnosed healthy group. All respondents reported their health on all 
GPBMs and subjective well-being measures, while only respondents in each disease group 
reported their health on the DSM for that particular group. This allowed comparisons with the 
most widely used DSMs in the different chronic disease areas, as well as with well-being 
measures. The selection of DSMs was based on reviews of the literature and advice from 
researchers from the different areas [110].  
A global survey company, CINT Pty Ltd, invited individuals registered in their database to 
participate in an online survey [110]. Respondents were initially asked to rate their overall 
health on a VAS of 0-100, where 0 represented the least desirable health you could imagine  
 
28 
Table 3. Respondents by disease group and country 
 
and 100 represented the best possible health (physical, mental, and social), and to indicate if 
they had any chronic diseases. Respondents were placed in the non-diagnosed healthy group 
if they reported no chronic disease and an overall health rating of at least 70 on the VAS. In 
each country, quotas were used to provide a demographically representative sample according 
to age, sex, and education. For each of the seven disease groups, a quota of 150 respondents 
was sought. To ensure the quality of the data, a series of editing criteria were used to eliminate 
unreliable respondents, e.g. those who completed the survey in less than 20 minutes (median 
was 40) and inconsistency in response to duplicated questions. Based on the eight edit criteria 
provided to eliminate unreliable answers, a total of 17% of respondents were excluded. 
Eventually, a total of 7933 respondents were included in the dataset. For further details on 
respondent recruitment, see Richardson et al. [110]. 
Diseases Australia UK USA Canada Norway Germany Total 
Asthma 141 150 150 138 129 147 855 
Cancer 154 137 148 138 80 115 772 
Depression 146 158 168 145 140 160 917 
Diabetes 168 161 168 144 143 140 924 
Hearing loss 155 126 156 144 113 136 830 
Arthritis 163 159 179 139 130 159 929 
Heart diseases 149 167 170 154 151 152 943 
Healthy group 265 298 321 328 288 260 1760 
Total 1341 1356 1460 1330 1174 1269 7933 
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In Papers 1 and 3, the full sample (N=7933) was employed, while in Paper 2 only the 
individuals diagnosed with depression (N=917) were included. A summary of the study 
sample by disease group and country is shown in Table 3. 
 Health outcome measures  
In all papers in this thesis, the most widely used GPBM, the EQ-5D-5L, has a central role. In 
Papers 1 and 2, the EQ-5D-5L utility index was applied, while in Paper 3 the focus is on the 5 
dimensions of the EQ-5D-5L descriptive system.  
GPBMs   
In Paper 1, the EQ-5D-5L, SF-6D (derived from SF-36), HUI-3, and 15D were applied (see 
Table 1). The EQ-5D-5L utility index was calculated using the new English value set based on 
a representative sample of the English public (N=996) [67]. For the SF-6D utility index, a UK 
value set based on a representative sample of members of the UK general population was 
used (N=836) [55]. The HUI-3 utility index was calculated using a representative sample of 
adult Canadians (N=504) [57], and the 15D utility index used a value set based on five 
random samples of the Finnish general population (N=2500) [111]. An overview of valuation 
techniques is presented in Table 2. In Paper 2, in addition to the new English value set, other, 
directly-elicited, country-specific EQ-5D-5L value sets were applied, including the 
Netherlands, Spain, Canada, China, Japan, Korea, and Uruguay [67,83,112-117].  
Disease-specific measures 
The DASS-21 comprises 21 items, each with a 4-point severity scale (did not apply to me; 
applied to some degree; applied to a considerable degree; applied very much or most of the 
time) [118]. It comprises three 7-items subscales that measure core symptoms of depression, 




The K10 measures psychological distress and comprises 10 items on anxiety and depressive 
symptoms experienced in the last 4 weeks [119]. Each item has five response levels (all the 
time; a little of the time; some of the time; most of the time; all of the time), resulting in a 
total score range of 10 to 50, where lower values indicate fewer problems.  
 Analysis  
3.3.1 Comparing GPBMs 
Paper 1 examined non-linearity among four GPBMs (EQ-5D-5L, SF-6D, HUI-3, and 15D) 
across different severity levels using QRM. It also investigated the exchange rates for these 
GPBMs. 
Testing non-linearity 
QRMs were used to study the relationship between pairs of GPBMs. The strength of  this 
approach is that it permits us to explore the entire conditional distribution by analyzing the 
effects of one GPBM (the source) at different levels of another GPBM (the target) [120]. 
Thus, unlike ordinary least squares (OLS) regression, which focuses on the conditional mean 
of the dependent variable, the QRM tests if the relationship between two GPBMs varies at 
different quantiles of the dependent variable. (For a theoretical background on QRM, see 
Koenker and Hallock [121]). Furthermore, in comparison to ordinary linear regression, the 
QRM is more robust to outliers and is semi-parametric, avoiding the assumptions about the 
parametric distribution of the error terms [122]. Thus, following Koenker and Bassett [123], 
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where Yi is an outcome variable (target instrument), Xi is the independent variable (source 
instrument), β(q) is the vector of parameters to be estimated for each quantile (q) under 
consideration, i  is error term, and  0<q<1 indicates the proportion of the population with 
scores below the quantile specified. Formulation of QRM requires that the 
thq  quantile of the 
error term be zero; and hence )( )()( i
q
ii
q XXYQuant  . Thus, the quantile regression 
estimator for the 
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where variables and parameters were defined  as in Equation (1). The residuals are measured 
using a weighted sum of vertical distances (without squaring), where the weight is 1 – q for 
points below the fitted line and q for points above the line. The ability to estimate parameters 
appropriate for the chosen quantiles other than the median is a unique feature of QRMs. In 
this thesis, a simultaneous QRM was applied to estimate the effect of the independent/source 
variable at nine different quantiles of the outcome/target variable; that is, the 10th, 20th, 30th, 
40th, 50th (median), 60th, 70th, 80th, and 90th percentile. This allows us to test if the association 
between two instruments differs across severity levels.   
Wald F-statistics were used to test for equality of coefficients across the quantile regression 
results. The degree of non-linearity between GPBMs was calculated by dividing the highest 
coefficient in each estimation by the lowest coefficient, referred to as the maximum degree of 
differences in coefficients (MDDC). To inquire into variations in the degree of non-linearity 





The exchange rates (ERs) presented in this paper differ from those used in traditional 
mapping algorithms, which are usually derived from regression techniques (e.g. OLS). 
Instead, our ERs were based on individual-level data and a simple calculation relying on 
aggregate data where the utility scale of each GPBM was split into six utility intervals with 
0.2 successive decrements in utility starting from perfect health at 1.00. That is, <0.2, [0.2, 
0.4), [0.4, 0.6), [0.6, 0.8), [0.8, 1), 1. Scale-dependent ERs were developed, and defined as the 
change in utilities measured using GPBM i (∆Ui) divided by the change in utilities measured 
using GPBM j (∆Uj): 
 
                                              𝐸𝑅𝑖𝑗 = ∆𝑈𝑖 ∆𝑈𝑗⁄                                     (1.3)          
 
This enabled comparisons at different intervals across the health state utility scale, which may 
give a truer picture of the real change in utility when transforming utility gains across 
instruments, especially changes at the more extreme parts of the utility scale. 
A bootstrap method was chosen to calculate the 95% confidence intervals for each ER. The 
method randomly draws a 60% sample from the full sample to calculate the ER and replicates 
the procedure 1000 times. 
3.3.2 Predicting EQ-5D-5L utilities  
In Paper 2, the mapping of depression scales (measured by DASS-21 and K10) onto eight 
country-specific EQ-5D-5L value sets was examined using six different regression models. 





Initially, the dimensional structure of the EQ-5D-5L, DASS-21, and K10 were investigated 
using Spearman’s rank correlation and exploratory factor analysis to provide insights into the 
conceptual overlap of the target and source measures. This could also inform the choice of the 
method applied for mapping, i.e. between a direct or an indirect (response) mapping approach 
[124]. Results of exploratory factor analysis revealed that all items on the depression scales 
were loaded onto the ‘depression’, ‘anxiety’, or ‘stress’ factors. However, the only EQ-5D-5L 
dimension that overlaps in any substantial way with these factors was the anxiety/depression 
dimension that loaded on the depression factor. Thus, the probability of accurately predicting 
five response levels for all the dimensions of the EQ-5D was low. In general, response 
mapping depends on the correct predictions for each dimension of the EQ-5D to make an 
exact prediction of a health state. Consequently, response mapping can be severely penalized 
when an incorrect prediction is made [125]. Thus, a direct mapping technique was applied to 
predict the EQ-5D-5L utility index (the dependent variable) using the source instrument, 
either the DASS-21 subscale score or the K10 total score (the independent variable). In 
addition to the source instrument, age and sex were considered as covariates. 
Regression models  
Six alternative models were compared, including OLS, the generalized linear model, the MM-
estimator, the censored least absolute deviations model, the FRM, and the BB regression 
model. For each model, a forward stepwise selection method was used for variable selection 
(p<0.05). Interaction and squared terms were considered only if the original variable was 
significant. FRM and BB regression provided optimal mapping functions for predicting EQ-
5D-5L utility values from both the DASS-21 and K10. Therefore, a detailed description of 
these models is presented in the next section. 
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FRM involves a semi-parametric approach that was developed to address the modeling of 
empirically-bound dependent variables, such as proportions and percentages, that exhibit 
piling-up at one of the two corners [126]. The advantages of FRM are several: (a) it does not 
require any special correction of the values observed at the bounds, (b) it accounts for the 
non-linearity in the data, and (c) it allows for direct recovery of the regression function for the 
dependent variable given the set of predictors1. Following Papke and Wooldridge [126], the 
basic assumption underlying the FRM can be summarized as: 
 
         )()|( XGXYE        (2.1) 
 
where G(·) is a known non-linear function satisfying 0 ≤ G(·) ≤ 1, X is a vector of 
independent variables, and β is a vector of parameters to be estimated. This is well defined if 
Yi takes any value in the specified range including 0 and 1 with positive probability. Unlike 
other parametric methods, the important advantage of this semi-parametric FRM is that it 
does not make any distributional assumption about an underlying structure used to obtain Yi. 
Several examples of non-linear functional forms are used for G (·). The logistic link function 
is the most widely applied functional form and is a natural choice for modelling bounded 
data, since it ensures that 0 < E(Y|X) < 1. It must be directly estimated using a non-linear 












)|(      (2.2) 
 
                                                     
1 In the FRM model, EQ-5D-5L utility values are linearly transformed onto a 0-1 scale by subtracting the 
minimum value from observed utilities of EQ-5D-5L and then dividing by the range.  
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The non-linear parameters of the model defined by Equation (2.1) may be estimated using a 
quasi-maximum likelihood method via the maximization of the Bernoulli log-likelihood 
function: 
 
   )(1log)1()(log)(  iiiii XGYXGYLL        (2.3) 
 
which is well defined for 0<G(.)<1. The quasi-maximum likelihood estimator of β is 
consistent and asymptotically normal, regardless of the true distribution of the dependent 
variable, conditional on the predictors, provided that Equation 2.1 is correctly specified, 
which can actually be tested using the RESET test [127].  
BB regression is a similar method for modelling bounded data. It involves a fully parametric 
approach that allows the dependent variable to be skewed and is capable of modeling bounded 
dependent variables restricted between 0 and 1. As this parametric model is not defined at the 
boundary values, the outcome values should be restricted to a 0-1 range, excluding 0 and 1. 
This can be achieved by linear transformation [Y(N-1)+0.5]/N following earlier literature 
[128,129], where N refers to sample size, and Y is the dependent variable. BB regression is 
flexible and allows a great variety of asymmetric forms. The most popular choice to estimate 
Equation 2.1 is the parametric beta distribution, see Khan and Morris [130] for applications of 
the beta binomial regression model. However, Khan and Morris used an inflated BB when 
mapping onto the EQ-5D, due to piling of responses at 1. This was not an issue in the MIC 
project depression sample (less than 2% reported the utility of 1). Following re-
parameterization of Ferrari and Cribari-Neto [131], beta regression is a fully parametric 
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where ᴦ(.) denotes the gamma function 0<Y<1, and the parameter μ denotes the expected 
value of Y; that is, E(Y)=μ; and φ dispersion parameter. The parameter φ can be interpreted as 
a precision parameter, because for fixed μ, the greater the value of φ, the smaller the variance 
















YVar           (2.5) 
 
Again, using logit as a link function (Equation 2.2), the BB regression for Yi (EQ-5D-5L) 
with X (DASS-21 subscales or K10 total scale) as independent predictor(s), and β as a vector 
of parameters is given as: 
 










                 (2.6) 
 
It is also possible to model the dispersion in terms of the independent predictors instead of 
assuming it is a nuisance parameter. However, since modeling the precision parameter 
separately barely adds to the prediction performance of the model, we considered Equation 
2.1 and 2.6 alone, assuming φ is a nuisance parameter for the sake of parsimony.  
Model performance  
To assess the predictive performance of each model in Paper 2, common criteria in mapping 
studies were applied: mean absolute error (MAE) and root mean square error (RMSE) 
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[20,21]. Due to a different number of independent variables across models, the degree of 
freedom was adjusted for both MAE and RMSE. Since a wider scale length of the dependent 
variable produces larger error [132], adjustment for scale differences was performed to allow 
reasonable comparisons between datasets or models with different scales. Both MAE and 
RMSE were normalized to the range (defined as the difference between the maximum and the 
minimum values) of the measured data. For instance, when applying the English value set, the 
MAE and RMSE were divided by the range of the data (1.17) as estimated by OLS, but they 
were divided by 0.998 when estimated by BB regression (since BB requires the 
transformation of values to be restricted between 0 and 1). In comparison, when estimated by 
OLS and applying the Dutch and Japanese value sets, MAE and RMSE were divided by 1.41 
and 0.88, respectively. Lastly, the performance of each model was also assessed by the square 
of the correlation coefficient between the observed and predicted values adjusted for the 
number of predictors in the model (adj. r2) [133].  
To investigate the generalizability of the preferred mapping algorithms, cross-validation was 
performed by splitting the existing data in two: estimation and validation samples via random 
selection procedures. In this study, the total sample was randomly divided into two equally-
sized groups to evaluate the model fit in out-of-sample data. The model was fitted on the 
estimation sample, and the resulting parameters from the fitted model were then used to 
predict the EQ-5D-5L in the validation sample. This procedure was then repeated by 
reversing the validation and estimation sample. The average MAE, RMSE, and r2 for both 
iterations were calculated to compare of the models’ predictive performance. Lastly, the best-
fitting model was estimated using the full sample (N=917).  
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3.3.3 Testing the relationship between EQ-5D-5L dimensions 
In Paper 3, the causal relationship between EQ-5D-5L dimensions was explored by specifying 
a number of testable models that specified EQ-5D-5L items as causal indicators or effect 
indicators of HRQoL. Model 1 specified all five EQ-5D-5L items as effect indicators of the 
construct HRQoL, whereas Models 2, 3, and 4 are multiple-cause multiple-indicator models. 
Model 2 tested whether the symptom items pain/discomfort and anxiety/depression should be 
treated as causal indicators and whether the activity/participation items mobility, self-care, 
and usual activities should be treated as effect indicators. On the other hand, Model 3 treated 
the symptom items pain/discomfort, anxiety/depression, and mobility as causal indicators, and 
self-care and usual activities as effect indicators. Model 4 was a variant of Model 3, where 
mobility had an intermediate position between pain/discomfort and the construct. See Paper 3 
in appendix for illustrations of the models. In addition, due to the uncertain nature of 
anxiety/depression and the investigation of reverse causality, alternative models were 
specified (see Paper 3 in appendix for description of these models). 
Two model-testing approaches were selected to test the specified models: confirmatory tetrad 
analysis (CTA) and confirmatory factor analysis (CFA). However, due to the specification of 
mobility in Model 4, CTA is not appropriate; thus, Model 4 was tested by CFA only. CTA 
seeks to determine whether items of a latent variable should be treated as causal or effect 
indicators [134,135]. Unlike the general SEM, the CTA does not estimate parameters; it only 
tests model fit using Chi-square (2). Furthermore, differently from traditionally nested 
models, a nested CTA can determine if two models are nested in terms of model-implied 
vanishing tetrads, not parameters. A bootstrap tetrad test was used to minimize the problem of 
non-normality [136]. For a more detailed description of CTA, see Paper 3 in appendix. 
Considering CFA, maximum likelihood estimation is considered robust when using non-
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continuous data [137-139] or data that violate multivariate normality assumptions [140-142]. 
However, since maximum likelihood can be affected by deviation from normality [143], 
bootstrap standard errors (with 1000 bootstrap draws) were used [144].  
Several fit indices were used to examine the model fit to data, including the comparative fit 
index, the Tucker-Lewis index, root-mean square error of approximation, the standardized 
root-mean square residual, the Akaike information criterion, and the sample-size adjusted 
Bayesian information criterion. A comparative fit index and Tucker-Lewis index value greater 
than 0.95, and a standardized root-mean square residual value less than 0.08, represent a well-
fitting model [145]. Root-mean square error of approximation values less than 0.05 reflect a 
good fit [146], and values as high as 0.08 reflect an adequate fit [147]. Akaike information 
criterion and sample-size adjusted Bayesian information criterion are only meaningful when 
different models are compared, and models with the lowest values represent those with the 
best fit. 
4 Results 
 Paper 1: Non-linearity across generic preference-based measures 
The results of Paper 1 revealed differences across the EQ-5D-5L, SF-6D, HUI-3, and 15D. 
Ceiling effects (utility=1) ranged from 1.4% (SF-6D) to 19.3% (EQ-5D-5L). The EQ-5D-5L 
and HUI-3 scales allow for utilities below zero, and have larger proportions at the bottom end 
of the scales. Because of the different scale lengths, the differences between health state 
utilities varied depending on the range compared, with the largest differences observed at the 
10th percentile, which implies that the potential utility gain involved from a cure would differ 
a lot depending on the GPBM used. Mean utilities varied from 0.71 (SF-6D and HUI-3) to 
0.85 (15D), while median utilities ranged between 0.70 (SF-6D) and 0.88 (15D). Mean and 
median utility for EQ-5D is 0.83 and 0.87, respectively 
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The key findings from Paper 1 were that non-linear relationships were evident across all four 
GPBMs. QRMs revealed that coefficients varied across all quantiles, implying that the 
strength of the relationship across GPBMs varies across the distribution of the target measure. 
For instance, when regressing any of the other GPBMs onto EQ-5D-5L, the effect is largest at 
the 0.1 quantile, then decreases, with the lowest effect at 0.9 quantile. Considering 15D as the 
source measure, the coefficient at the lower quantile of EQ-5D-5L was more than double (1.8, 
p<0.001) that of the upper quantile (0.7, p<0.001). The different effect of all GPBMs across 
the EQ-5D-5L distribution was supported by Wald F-tests, indicating a significant difference 
(p<0.01) between coefficients, which rejected the null hypothesis of the equality of 
coefficients across quantiles. This was also shown when regressing onto the other three 
GPBMs. For HUI-3 and 15D, a similar pattern of the coefficients across quantiles was 
observed, while for SF-6D the strongest effect was on the 0.6 quantile (15D) and 0.7 quantile 
(HUI-3 and EQ-5D-5L) and lowest at the 0.1 quantile. Except when regressing HUI-3 and 
15D onto SF-6D in the depression group, all tests indicated that there was a significant 
difference (p<0.01) between coefficients. 
The degree of non-linearity across the full study sample and in all seven disease groups was 
investigated by calculating the ratio between the highest and the lowest coefficients, referred 
to as the MDDC at each estimation. For instance, when regressing SF-6D onto EQ-5D, the 
highest coefficient was at the 0.1 quantile and the lowest at the 0.9 quantile (MDDC: 
1.37/0.41=3.34). The degree of non-linearity was largest for EQ-5D-5L (MDDC: 2.49-3.34) 
and HUI-3 (MDDC: 2.05-3.48) and smallest for SF-6D (MDDC: 1.26-1.32). Similar results 
were found when looking into the seven disease groups. 
The scale-dependent exchange rates further revealed the non-linear relationships. The ERs 
were calculated based on a change in mean utilities of the target measure at different utility 
intervals of that measure. For instance, the ERs between each utility interval on the 15D scale 
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indicate the value by which a 15D increment has to be multiplied to get the corresponding 
change in utility had the EQ-5D been applied. As an example, take the ERs between 15D and 
EQ-5D-5L. If 15D had been applied in a study where the patient group at baseline was in the 
0.4-0.6 interval with a mean utility of 0.53, and after treatment they were in the 0.6-0.8 
interval with a mean utility of 0.72, it would represent an increase of ∆U15D=0.19 on the 15D 
utility scale. The corresponding increment on the EQ-5D-5L scale would be from 0.38 to 0.67 
(∆UEQ-5D =0.29). Hence, the 15D increment has to be multiplied by an exchange rate of 1.51 
(∆UEQ-5D / ∆U15D) to make the utility increment comparable to the increment had the EQ-5D-
5L been applied.    
 Paper 2: Mapping from disease-specific to generic measures 
The results of Paper 2 showed that both mean EQ-5D-5L utility values and the range of these 
values varied depending on the choice of country-specific value sets. The mean EQ-5D-5L 
utility ranged from 0.59 in the Dutch value set to 0.83 in the Uruguayan value set, while the 
minimum utility value ranged from -0.41 in the Dutch value set to 0.12 in the Korean and 
Uruguayan value set. Such differences across value sets suggest that a separate mapping 
algorithm needs to be estimated. 
Spearman’s rank correlation indicated that the EQ-5D-5L anxiety/depression dimension 
produced the highest correlation with the source measures (r ≥0.50), while the mobility 
dimension produced the lowest (r ≤0.25). In addition, the EQ-5D-5L usual activities 
dimension correlated moderately (r=0.35 to 0.37) with DASS-anxiety, DASS-depression, and 
the K10 scale. Exploratory factor analysis revealed that only the EQ-5D-5L anxiety/depression 
dimension overlapped with the depression dimensions extracted for both the DASS-21 and 
the K10. The remaining four EQ-5D-5L items were mainly loaded on the fourth factor (i.e. 
physical functioning), with no high cross-loadings (>0.30).  
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In the evaluation of model performance, FRM performed best in the majority of goodness-of-
fit measures, i.e. adjusted-r2, normalized MAE and normalized RMSE, for both DASS-21 and 
K10. The only exception was for the Japanese value set, for which BB regression was the 
preferred model. Although median estimators (censored least absolute deviations and MM-
estimator) generally performed best in terms of normalized MAE, they performed poorly on 
the other two measures.  
When DASS-21 was the source measure, the best fitting regression results included 
depression subscale scores, anxiety subscale scores, and age as significant (p<0.05) predictors 
in all models. When K10 was the source measure, K10 total score and age were significant 
(p<0.05) predictors.  
 Paper 3: Causal links across health-related quality of life dimensions 
Paper 3 explored the causal pattern among the five dimensions of EQ-5D-5L. Frequency 
distribution of EQ-5D-5L health states revealed that the three most prevalent health states (i.e. 
11121, 11112, 11122) accounted for more than one third of the sample that was in a non-
11111 health state. When including other health states with decrements in symptom 
dimensions only, almost half of the sample (i.e. 47%) was accounted for. In contrast, our 
findings revealed that decrements in activity/participation dimensions are rarely reported 
without any decrements in symptoms (i.e. 1.5% of the sample). Additionally, the relationship 
between summary scores of symptom dimensions and summary scores of 
activity/participation dimensions (see Figure 3 in the appendix of Paper 3 for illustration of 
the result), indicated that increasing symptoms are associated with more problems in 
activity/participation dimensions. However, it appears that problems with 
activity/participation lag behind problems in symptom dimensions.  
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The result of the two SEM approaches applied (CTA and CFA) indicated support for Model 
3, which specifies mobility, pain/discomfort, and anxiety/depression as causal indicators, and 
self-care and usual activities as effect indicators (see Figure 4 in the appendix of Paper 3).  
The results of the CTA for Model 1 (2=1500.00, degree of freedom, df=15), Model 2 
(2=893.79, df=6), and Model 3 (2=105.84, df=3) revealed highly significant 2 estimates 
(P<0.0001). Model 3 clearly produced the lowest 2 estimates, suggesting it was the best 
model. Although the significant 2 estimate indicated that the model was a poor fit to the data, 
it is common for 2 estimates to be significant in large samples [148].  A nested CTA test that 
compared Model 2 and Model 3 revealed a highly significant 2 difference (2 diff=787.62, 
df=6, p<0.0001), favoring for the model with fewest vanishing tetrads (Model 3). 
When looking at the results of CFA, the fit indices suggested a similar satisfactory fit to the 
data. For Model 3 and Model 4, the comparative fit index and Tucker-Lewis index were 
greater than 0.95, the root-mean square error of approximation was lower than 0.08, and the 
standardized root-mean square residual was 0.12 and 0.16, respectively. However, the Akaike 
information criterion and sample-size adjusted Bayesian information criterion for Model 3 
(Akaike information criterion=20400.537; Bayesian information criterion=20434.746) was 
preferred when compared to Model 4 (Akaike information criterion=36580.861; Bayesian 
information criterion=36626.472).  
An alternative model specifying the anxiety/depression dimension as an effect indicator along 
with self-care and usual activities did not produce a good fit, either with CTA (2=927.93, 
df=6, p<0.0001) or CFA (comparative fit index=0.965; Tucker-Lewis index=0.922; root-
mean square error of approximation=0.122; standardized root-mean square residual=0.026). 
Further models investigated other specifications of the interrelationships among the three 
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causal indicators (mobility, pain/discomfort, and anxiety/depression) in Model 4. All these 
models had a poor fit compared to the chosen model.  
5 Discussion 
 Methodological issues 
5.1.1 Study design 
The MIC project is the largest international project designed to make comparisons and 
transformations across GPBMs, as well as commonly used DSMs [110]. There was a growing 
amount of literature on the dissimilarities and lack of agreement across the existing methods 
for measuring and valuing HRQoL. Thus, the motivation for the MIC project was to assess 
this discrepancy, and the project generally aims to contribute to the methodological 
development of the field of measuring HRQoL.  
The MIC project has a cross-sectional design and includes respondents from six countries 
with a diverse range of health states that are associated with major chronic diseases, as well as 
a non-diagnosed healthy group. The aim of this thesis overlaps with that of the MIC project, 
i.e. to compare and transform measures (making the MIC data appropriate for the research 
questions posed in this thesis).                                                                                                                                                                                                                               
All the three papers in this thesis are exclusively based on data from the MIC project. While 
Papers 1 and 3 included the full study sample, which included seven disease groups and a 
non-diagnosed healthy group, Paper 2 included the depression subsample only. Mean age in 
the full sample was 51.5, and sex was more equally distributed (female=52.2%). Moreover, 
respondents in the depression subsample were younger (mean age is 42) and this group 
consisted of more women (65.9%). Previous studies have also shown that the prevalence of 
depression is commonly higher among women and younger individuals [25,149].   
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The MIC project survey was administered by an online survey company, CINT, that invited 
individuals registered in their database to participate. Initially, respondents were asked about 
diagnoses they had received regarding any of the seven diseases, and based on their reply they 
were placed in either the healthy group or the disease group. A target number of respondents 
were sought for each of the seven disease groups. Respondents would then proceed to answer 
the core questionnaire containing GPBMs and DSM(s) until the quota was reached for the 
group to which they were assigned. Due to this recruitment procedure, the issue of “response 
rate” becomes less relevant. However, 83% of responses were retained after the stringent 
criteria used in the editing process were applied to remove unreliable answers, which can be 
considered quite high.  
Self-selection may be an issue, since participants choose to register in the CINT online survey 
database and subsequently the MIC project survey. Nevertheless, the high retention of 
responses after the stringent editing procedure, as well as the large sample size, lends support 
to the high quality of the data. Furthermore, there is no missing information on any of the 
variables used in this thesis. This is due, in part, to the fact that all participants were required 
to respond to each item when responding to any of the HRQoL measures.     
5.1.2 Reliability and validity of HRQoL measures 
The four GPBMs (EQ-5D, SF-6D, 15D, HUI-3) and the two DSMs (DASS-21 and K10) 
employed in this thesis have broad and extensive applications. The four GPBMs were 
selected because they were used in more than 98% of studies that measured and valued 
QALY gains [19], while the DASS-21 and K10 are among the most widely used mental 
health scales applied to identify emotional disturbance by assessing core symptoms of 
depression, anxiety, and stress. All measures have previously been validated in different 




The generic and disease-specific measures applied in this study have shown satisfactory 
reliability in previous studies, as well as in this thesis. Reliability refers to the overall 
consistency of a measure [1]. Three types of consistency should be considered: test-retest 
reliability, i.e. if the measure produces similar results under the same conditions over time; 
inter-rater reliability, i.e. if the measure produces similar results across different observers 
assessing the same person; and finally internal consistency, i.e. if the measure produces 
similar results across items of the measure. While previous studies have shown evidence of 
test-retest and inter-rater reliability of GPBMs [150,151], the data from the MIC project did 
not include measurement at different time points nor from different observers’ perspectives. 
However, internal consistency, commonly measured by Cronbach’s alpha, indicated the 
consistency of individuals’ responses across the items of a measure. In Table 4, except for 
HUI-3, all measures had a Cronbach’s alpha coefficient above 0.80, which is indicative of 
good internal consistency [152]. The lower alpha coefficient produced by HUI-3 may be due 
to the definition of health that is used in its development. Indeed, the HUI-3 does not focus on 
“beyond the skin aspects of health” and mainly assesses impairments of body functions and 
disability. This may lead to lower inter-item correlations, and consequently a lower Cronbach 
alpha [57].  
Validity 
A valid measurement scale measures what it is intended to measure, which cannot be 
established by high reliability alone [152]. Important aspects of validity are content and 
construct validity. Content validity is the extent to which a measure covers the health 
dimensions of interest and is sufficiently sensitive to change [152]. Convergent and 
discriminant validity are the two subtypes of validity that make up construct validity.  
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 Table 4. Reliability and validity of HRQoL measures  
Note. Full sample applied above midline (N=7933); Depression subsample applied below midline (N=917). 
MH=mental health; RE=role emotional; SF=social function; VT=vitality; BP=bodily pain; RP=role physical; 
PF=physical functioning; GH=general health.  
aKruskal-Wallis H test statistics to test  known-group validity across education levels (1=High school; 
2=Diploma;3=University).  
bAmong the four GPBMs, the highest correlation coefficients for SF-6D should be expected, given it is a “short-
form” of the full SF-36. 
*All Pearson correlation coefficients are significant at p<0.001. 
 
Convergent validity refers to the degree to which a measure correlates positively with a 
theoretically similar measure, while discriminant validity is the extent to which a measure 
does not correlate with scores on measures that are conceptually distinct [152]. 
In this thesis, content and convergent validity were assessed by investigating how the GPBMs 
and DSMs correlated with the eight health dimensions of the SF-36. The GPBMs produced 
moderate to large correlations across SF-36 subscales, while for DSMs, large correlations 
were produced with the SF-36 mental health dimension, and weaker correlations with other 
SF-36 dimensions e.g. physical functioning and bodily pain. The weaker correlations for the 
DSMs with the physical health dimensions of the SF-36 are indicative of discriminant 
validity. As seen in the last column of Table 4, discriminant validity was also indicated by the 
ability of the measures to discriminate between known groups (education levels).  
 SF-36 subscales*   




2        p-level 
EQ-5D-5L 0.57 0.48 0.65 0.62 0.71 0.55 0.70 0.63 0.81 68.209 0.0001 
SF-6Db 0.71 0.70 0.80 0.76 0.73 0.71 0.67 0.69 0.84 47.696 0.0001 
HUI-3 0.60 0.48 0.64 0.63 0.66 0.54 0.67 0.63 0.69 119.515 0.0001 
15D 0.62 0.53 0.68 0.72 0.69 0.61 0.71 0.73 0.88 87.256 0.0001 
DASS-D 0.73 0.40 0.55 0.55 0.24 0.27 0.27 0.41 0.92 14.767 0.0006 
DASS-A 0.58 0.33 0.46 0.37 0.33 0.33 0.35 0.41 0.84 22.863 0.0001 
DASS-S 0.60 0.33 0.42 0.40 0.24 0.25 0.23 0.35 0.86 12.979 0.0015 




Some studies have also revealed the validity of the GPBMs (for instance see Finch et al. [153] 
and Richardson et al. [17]). Although there is no gold standard that HRQoL measures can be 
compared with, the validity of measures applied in this thesis was acceptable, which was 
supported by evidence in the literature.  
 Discussion of results 
The major aim of this thesis was to provide a better understanding of GPBMs used in 
economic evaluations to assign health state utilities, with particular emphasis on the most 
widely used measure, the EQ-5D. Paper 1 focused on the comparability across four GPBMs: 
the EQ-5D-5L, SF-6D, HUI-3, and 15D. Quantile regressions revealed that the EQ-5D-5L has 
strong non-linear relationships with all the other GPBMs, and this finding was consistent 
across the seven disease groups. For instance, the MDDC (i.e. the ratio between the highest 
and the lowest coefficients across quantiles) ranged from 2.05 to 3.39. This indicates that 
across the full sample and subsamples, the coefficient estimated at the 0.1 quantile was at 
least twice the size of the coefficient estimated at the 0.9 quantile. These findings support 
other studies that have indicated non-linear relationships across GPBMs [23,24,92]. The 
scaling effect could be a key factor in explaining the observed non-linear relationship [16]. 
For instance, a recent study by Whitehurst et al. [93] compared EQ-5D and SF-6D responses 
from seven patient datasets using published DCE-derived scoring algorithms against previous 
conventional EQ-5D-3L and SF-6D index scores, and found that SF-6D produced 
consistently lower values for severe health states, which is contrary to previous findings. This 
suggests that the ‘floor effect’, or the worst health states, in SF-6D compared to EQ-5D-3L 
can be explained by the technique used for valuation, while the remaining 
incommensurability is due to differences in the descriptive system [1]. Furthermore, we 
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confirmed earlier findings from Seymour et al. [92] that the effect of the EQ-5D differs at 
different parts of the SF-6D distribution. While the degree of non-linearity in the current 
paper was less for the SF-6D than for the EQ-5D-5L, the non-linearity was still replicated 
across all disease groups, with only one exception in the depression subsample, where linear 
relationships were indicated between the SF-6D and both the 15D and HUI-3. This implies 
that there may be a constant exchange rate between the SF-6D and 15D as well as the HUI-3, 
irrespective of severity levels.   
Compared to the OLS coefficient, quantile regression revealed that the consequences of 
applying OLS regression when estimating mapping algorithms across all GPBMs would over-
predict utility for respondents with poor health and under-predict utility for respondents with 
moderate to good health, except for the SF-6D where this tendency is reversed. This may be 
because SF-6D is more sensitive among respondents with better health (only 1.4% have 
utility=1), as well as the lesser preference weights attached to the more severe health states as 
compared to others. In general, the problem of overestimating utilities in respondents with 
poor health when mapping across GPBMs persists [24]. Our results further strengthen the 
claim that non-linear associations are important to take into account when comparing 
healthcare programs whose effectiveness have been measured by different GPBMs. 
In Paper 2, the primary aim was to develop mapping algorithms to estimate EQ-5D-5L health 
state utility values from two widely used depression-specific measures. The findings showed 
that the mapping algorithms differed across country-specific value sets, which indicated that 
the strength of preferences for the different health dimensions in EQ-5D-5L is culture-
dependent. Thus, country-specific mapping algorithms should be applied to estimate utilities 
for a particular country.   
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An earlier study mapped the DASS-21 and K10 onto EQ-5D-5L using the interim UK cross-
walk value set [102]. Although both studies applied the same data, the results were not 
directly comparable due to the difference in value sets, regression models, and choice of 
covariates. In order to better compare the studies, the MAE and RMSE used therein were 
normalized, as they were in the current study. This produced a normalized MAE and 
normalized RMSE of 0.119 and 0.159, respectively, for the DASS-21, and 0.115 and 0.154, 
respectively, for the K10. In the previous study, the OLS model was preferred over the 
generalized linear model. In the current study, the FRM produced lower estimates for both the 
DASS-21 and the K10, indicating better predictive performance when the English value set 
was applied. Furthermore, among the eight country-specific value sets in the current study, 
prediction accuracy was best when using the Uruguayan value set for both the DASS-21 
(normalized MAE=0.099; normalized RMSE=0.138) and the K10 (normalized MAE=0.097; 
normalized RMSE=0.138) and worst for Canada for both the DASS-21 (normalized 
MAE=0.132; normalized RMSE=0.175) and the K10 (normalized MAE=0.128; normalized 
RMSE=0.175).  
The FRM showed the best fit in all cases except Japanese values, for which BB regression 
model was preferred. It is not surprising that different models may fit different country-
specific value sets. Mapping is data-dependent, which is one of the key reasons why different 
econometric methods need to be tested and then based on goodness-of-fit estimates to identify 
the optimal one. The possible explanation for the choice of different model for the Japanese 
value set could be dissimilarities in the distribution of the preference pattern compared to 
other country-specific value sets. A previous study compared value sets from seven countries 
(four Western, two Asian, and one South American) and found that the Western value sets 
had more or less a similar pattern [154]. This resemblance in preference pattern could explain 
why the Western value sets fit the same model. On the other hand, this observation may 
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suggest that to derive an optimal mapping algorithm, different econometric techniques should 
be considered. 
Paper 3 focused on the causal and effect nature of EQ-5D dimensions. The aim was to 
develop a conceptual framework based on theoretical models suggested by the International 
Classification of Functioning, Disability and Health and Wilson and Clearly [155,156]. 
Specifically, symptom/impairments dimensions are causal indicators, while 
functioning/activities or participation dimensions are effect indicators.   
Investigation of commonly reported EQ-5D-5L health states in the current study revealed that 
decrements in symptom dimensions without decrements in activity/participation dimensions 
are common, while the opposite is rare. This finding suggest that problems with 
activity/participation are prevalence dependent on symptoms. Similar patterns of commonly 
reported EQ-5D-5L health states has been shown by others [157]. The suggestion that 
symptoms precedes problems in activity/participation dimensions was also supported by our 
result showing that increasing summary scores of symptom dimensions are associated with 
increasing summary scores of activity/participation dimensions, but that problems in the latter 
seem to lag behind.   
The result of CTA and CFA suggested that self-care and usual activities acted as effect 
indicators of HRQoL; and mobility, pain/discomfort, and anxiety/depression appeared to be 
causal in nature, driving changes in self-care and usual activities. Previous research has 
suggested that mobility may have an intermediate role [108], and while our results indicated 
that this is plausible, the model specifying mobility as causal produced a better fit.  
Studies have indicated that anxiety/depression and emotional functioning are effect indicators 
[108,158]. However, our results suggested that the anxiety/depression dimension is a causal 
indicator. There are reasons to believe that the role of anxiety/depression might vary 
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depending on the severity of these conditions. If the depression or anxiety is moderate or 
severe (levels 3-5), it could reflect more of a clinical symptom that may cause dysfunctions in 
self-care and usual activities that typically require treatment. If the condition is mild (level 2), 
it could be more subjective well-being, which may vary according to personality traits (e.g. 
optimist versus pessimist; level of neuroticism). Further investigation into the various disease 
groups might have indicated that the causal nature of anxiety/depression is disease-specific.  
6 Policy implications and future research 
 Policy implications 
 
The findings of this thesis have important implications for researchers and decision-makers 
involved in the economic evaluation of healthcare interventions and in setting priorities for 
the allocation of healthcare resources. Paper 1 showed that the result of a health intervention 
depends on the GPBMs used, implying that decision-makers would have a problem 
comparing QALY gains calculated with different GPBMs. We observed clear non-linear 
relationships, implying that the same exchange rate should not be applied across all levels of 
the utility scale.  
Paper 2 indicated that mapping the DASS-21 or the K10 onto the EQ-5D-5L is feasible when 
applying any of the country-specific value sets. The best-performing regression models imply 
that researchers should account for non-linearity of the data when performing mapping, as 
well as consider the model's appropriateness for bounded data. Thus, in the absence of EQ-
5D-5L utility, the preferred mapping model can adequately convert depression-specific scores 
into utility values. Due to the high prevalence and early onset of depression, enabling 
economic evaluation of clinical studies is very policy-relevant [159].  
 
53 
The findings of Paper 3 indicated that the EQ-5D-5L comprises both causal and effect 
indicators of HRQoL. Knowledge about the causal relationship among dimensions is 
important for researchers involved in developing new, and extending existing GPBMs (e.g. 
bolt-ons for EQ-5D). While adding effect indicators (i.e. social relationships) may make the 
EQ-5D more applicable across sectors (e.g. social care), adding a symptom indicator may 
make it more applicable to health care. However, focusing on effect indicators and the 
participation part of the health spectrum may be more in line with the aim of a generic 
measure, since it is not specific to particular health conditions. Nevertheless, sensitive 
GPBMs should probably comprise both types of dimensions. Whether causal or effect 
indicators should be emphasized is a question that is open for further research.  
 Future research 
In the absence of external data, existing datasets are commonly split into an estimation dataset 
and a validation dataset. However, mapping algorithms should ideally be validated using an 
external dataset that has not been used for estimation. Future studies should investigate the 
merit of the mapping results produced in this thesis by applying external data.  
Based on the WHO’s definition of health, it has been suggested that health economic 
evaluations should put more emphasis on the mental and social dimensions of health. An 
interesting question for future studies is whether a GPBM like the EQ-5D should broaden its 
operationalization of the HRQoL concept in the direction of effect dimensions (e.g. social 
connections/network or general well-being) or in the direction of causal dimensions (e.g. 
tiredness). Furthermore, since anxiety and depression are highly prevalent disorders and the 
most commonly reported comorbidities that more often occur together than alone [160,161], 
another solution that may improve the sensitivity of the EQ-5D-5L in mental health would be 




In conclusion, this thesis examined the degree of non-linear relationships across four GPBMs 
(EQ-5D-5L, SF-6D, HUI-3, and 15D) and then focused on the most widely used utility 
measure, the EQ-5D-5L, by i) mapping from depression-specific measures (DASS-21 and 
K10) onto EQ-5D-5L utilities; and ii) exploring the internal structure of the EQ-5D-5L 
descriptive system.  
The clear non-linear relationships observed across GPBMs make it difficult to compare 
QALY gains from studies that have applied different measures. Exchange rates that are scale-
dependent can convert a change in utility on a given measure into a corresponding utility 
change on another measure, which may enable a better comparison of the cost-effectiveness 
of competing health interventions that have been assessed by different GPBMs. Thus, 
accounting for non-linear relationships will increase the validity of such comparisons. 
The preferred mapping algorithm between depression-specific measures and EQ-5D-5L 
utility values adequately predict mean health state utility values, which facilitates economic 
evaluations of mental health interventions. Since different EQ-5D-5L value sets produce 
different utility values, especially at the lower end, the country-specific mapping algorithm is 
a better option to reflect the preference in a particular country. Thus, in the absence of utility 
data, the mapping algorithms enable the conversion of DASS-21 or K10 scores to a generic 
outcome metric like QALYs.   
A conceptual framework was developed based on theoretical models of HRQoL, which 
depicted the five dimensions in the EQ-5D-5L descriptive system as causal or effect 
indicators of HRQoL. Empirical testing of this framework supported that the EQ-5D-5L 
comprises causal indicators (mobility, pain/discomfort, anxiety/depression) and effect 
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Appendix 1: Generic preference-based measures applied  
SF-6D classification system (derived from SF-36) 
Physical Functioning     
 My health does not limit me in vigorous activities     
 My health limits me a little in vigorous activities     
 My health limits me a little in moderate activities     
 My health limits me a lot in moderate activities     
 My health limits me a little in bathing and dressing     
 My health limits me a lot in bathing and dressing     
Role limitations    
 I have no problems with my work or other regular daily activities as a result of my 
physical health or any    emotional problems    
 I am limited in the kind of work or other activities as a result of my physical health    
 I accomplish less than I would like as a result of emotional problems     
 I am limited in the kind of work or other activities as a result of my physical health and 
accomplish less than I would like as a result of emotional problems    
Social functioning    
 My health limits my social activities none of the time     
 My health limits my social activities a little of the time     
 My health limits my social activities some of the time    
 My health limits my social activities most of the time    
 My health limits my social activities all of the time    
Pain     
 I have no pain 
 I have pain but it does not interfere with my normal work (both outside the home and housework) 
 I have pain that interferes with my normal work (both outside the home and housework) a little bit 
 I have pain that interferes with my normal work (both outside the home and housework) moderately 
 I have pain that interferes with my normal work (both outside the home and housework) quite a bit 
 I have pain that interferes with my normal work (both outside the home and housework) extremely 
Mental health     
 I feel tense or downhearted and low none of the time     
 I feel tense or downhearted and low a little of the time     
 I feel tense or downhearted and low some of the time     
 I feel tense or downhearted and low most of the time    
 I feel tense or downhearted and low all of the time    
Vitality     
 I have a lot of energy all of the time    
 I have a lot of energy most of the time    
 I have a lot of energy some of the time    
 I have a lot of energy a little of the time    
 I have a lot of energy none of the time    
HUI-3 classification system (Please select the answer for each attribute that is correct for you) 
Vision                       
 Able to see well enough to read ordinary newsprint and recognize a friend on the other side of the street, 
without glasses or contact lenses. 
 Able to see well enough to read ordinary newsprint and recognize a friend on the other side of the street, 
but with glasses. 
 Able to read ordinary newsprint with or without glasses but unable to recognize a friend on the other side 
of the street, even with glasses. 
 Able to recognize a friend on the other side of the street with or without glasses but unable to read 
ordinary newsprint, even with glasses. 
 Unable to read ordinary newsprint and unable to recognize a friend on the other side of the street, even 
with glasses. 
 Unable to see at all. 
Hearing 
 Able to hear what is said in a group conversation with at least three other people, without a hearing aid. 
 Able to hear what is said in a conversation with one other person in a quiet room without a hearing aid, 
but requires a hearing aid to hear what is said in a group conversation with at least three other people. 
 Able to hear what is said in a conversation with one other person in a quiet room with a hearing aid, and 
able to hear what is said in a group conversation with at least three other people, with a hearing aid. 
 Able to hear what is said in a conversation with one other person in a quiet room, without a hearing aid, 
but unable to hear what is said in a group conversation with at least three other people even with a hearing 
aid. 
 Able to hear what is said in a conversation with one other person in a quiet room with a hearing aid, but 
unable to hear what is said in a group conversation with at least three other people even with a hearing aid. 
 Unable to hear at all. 
Speech 
 Able to be understood completely when speaking with strangers or people who know me well. 
 Able to be understood partially when speaking with strangers but able to be understood completely when 
speaking with people who know me well. 
 Able to be understood partially when speaking with strangers or people who know me well. 
 Unable to be understood when speaking with strangers but able to be understood partially by people who 
know me well. 
 Unable to be understood when speaking to other people (or unable to speak at all). 
Ambulation 
 Able to walk around the neighbourhood without difficulty, and without walking equipment. 
 Able to walk around the neighbourhood with difficulty, but does not require walking equipment or the 
help of another person. 
 Able to walk around the neighbourhood with walking equipment, but without the help of another person. 
 Able to walk only short distances with walking equipment, and requires a wheelchair to get around the 
neighbourhood. 
 Unable to walk alone, even with walking equipment. Able to walk short distances with the help of another 
person, and requires a wheelchair to get around the neighbourhood. 
 Cannot walk at all. 
Dexterity 
 Full use of two hands and ten fingers. 
 Limitations in the use of hands or fingers, but does not require special tools or help of another person. 
 Limitations in the use of hands or fingers, is independent with use of special tools (does not require the 
help of another person). 
 Limitations in the use of hands or fingers, requires the help of another person for some tasks (not 
independent even with the use of special tools). 
 Limitations in the use of hands or fingers, requires the help of another person for most tasks (not 
independent even with the use of special tools). 
 Limitations in the use of hands or finders, requires the help of another person for all tasks (not 
independent even with the use of special tools). 
Emotion            
 Happy and interested in life.                       
 Somewhat happy.                       
 Somewhat unhappy.                       
 Very unhappy.                       
 So unhappy that life is not worthwhile.                       
Cognition            
 Able to remember most things, think clearly and solve day to day problems. 
 Able to remember most things, but have a little difficulty when trying to think and solve day to day 
problems. 
 Somewhat forgetful, but able to think clearly and solve day to day problems.            
 Somewhat forgetful, and have a little difficulty when trying to think or solve day to day problems. 
 Very forgetful, and have great difficulty when trying to think or solve day to day problems. 
 Unable to remember anything at all, and unable to think or solve day to day problems.  
Pain            
 Free of pain and discomfort.                       
 Mild to moderate pain that prevents no activities.                       
 Moderate pain that prevents a few activities.                       
 Moderate to severe pain that prevents some activities.                       
 Severe pain that prevents most activities.                       
15D (Select the answer which best describes your present health status) 
Mobility                        
 I am able to walk normally (without difficulty) indoors, outdoors and on stairs.  
 I am able to walk without difficulty indoors, but outdoors and/or on stairs I have slight difficulties. 
 I am able to walk without help indoors (with or without an appliance), but outdoors and/or on stairs only 
with considerable difficulty or with help from others.  
 I am able to walk indoors only with help from others.             
 I am completely bed-ridden and unable to move about.             
Vision           
 
 I see normally, i.e. I can read newspapers and TV text without difficulty (with or without glasses).  
 I can read papers and/or TV text with slight difficulty (with or without glasses).  
 I can read papers and/or TV text with considerable difficulty (with or without glasses).  
 I cannot read papers or TV text either with glasses or without, but I can see enough to walk about without 
guidance.  
 I cannot see enough to walk about without a guide, i.e. I am almost or completely blind.  
            
Hearing            
 I can hear normally, i.e. normal speech (with or without a hearing aid).  
 I hear normal speech with a little difficulty.  
 I hear normal speech with considerable difficulty; in conversation I need voices to be louder than normal. 
 I hear even loud voices poorly; I am almost deaf.   
 I am completely deaf.    
Breathing                 
 I am able to breathe normally, i.e. with no shortness of breath or other breathing difficulty.   
 I have shortness of breath during heavy work or sports, or when walking briskly on flat ground or slightly 
uphill.   
 I have shortness of breath when walking on flat ground at the same speed as others my age.   
 I get shortness of breath even after light activity, e.g. washing or dressing myself.   
 I have breathing difficulties almost all the time, even when resting.  
Sleeping                 
 I am able to sleep normally, i.e. I have no problems with sleeping 
 I have slight problems with sleeping, e.g. difficulty in falling asleep, or sometimes waking at night.  
 I have moderate problems with sleeping, e.g. disturbed sleep, or feeling I have not slept enough.  
 I have great problems with sleeping, e.g. having to use sleeping pills often or routinely, or 
usually waking at night and/or too early in the morning.   
 I suffer severe sleeplessness, e.g. sleep is almost impossible even with full use of sleeping pills, 
or staying awake most of the night.   
Eating            
 I am able to eat normally, i.e. with no help from others.  
 I am able to eat by myself with minor difficulty (e.g. slowly, clumsily, shakily, or with special 
appliances).  
 I need some help from another person in eating.  
 I am unable to eat by myself at all, so I must be fed by another person.  
 I am unable to eat at all, so I am fed either by tube or intravenously 
Speach            
 I am able to speak normally, i.e. clearly, audibly and fluently.  
 I have slight speech difficulties, e.g. occasional fumbling for words, mumbling, or changes of pitch.  
 I can make myself understood, but my speech is e.g. disjointed, faltering, stuttering or stammering.  
 Most people have great difficulty understanding my speech.  
 I can only make myself understood by gestures.  
Elimination            
 My bladder and bowel work normally and without problems.  
 I have slight problems with my bladder and/or bowel function, e.g. difficulties with urination, or loose or 
hard bowels.  
 I have marked problems with my bladder and/or bowel function, e.g. occasional 'accidents', or severe 
constipation or diarrhea.  
 I have serious problems with my bladder and/or bowel function, e.g. routine 'accidents', or need of 
catheterization or enemas.  
 I have no control over my bladder and/or bowel function.       
Usual Activities                  
 I am able to perform my usual activities (e.g. employment, studying, housework, free-time activities) 
without difficulty.  
 I am able to perform my usual activities slightly less effectively or with minor difficulty.   
 I am able to perform my usual activities much less effectively, with considerable difficulty, or not 
completely.  
 I can only manage a small proportion of my previously usual activities.   
 I am unable to manage any of my previously usual activities.   
Mental Function                  
 I am able to think clearly and logically, and my memory functions well  
 I have slight difficulties in thinking clearly and logically, or my memory sometimes fails me.  
 I have marked difficulties in thinking clearly and logically, or my memory is somewhat impaired.  
 I have great difficulties in thinking clearly and logically, or my memory is seriously impaired.  
 I am permanently confused and disoriented in place and time.  
Discomfort and Symtoms                  
 I have no physical discomfort or symptoms, e.g. pain, ache, nausea, itching etc.  
 I have mild physical discomfort or symptoms, e.g. pain, ache, nausea, itching etc 
 I have marked physical discomfort or symptoms, e.g. pain, ache, nausea, itching etc.  
 I have severe physical discomfort or symptoms, e.g. pain, ache, nausea, itching etc 
 I have unbearable physical discomfort or symptoms, e.g. pain, ache, nausea, itching etc.  
Depression            
 I do not feel at all sad, melancholic or depressed.            
 I feel slightly sad, melancholic or depressed.             
 I feel moderately sad, melancholic or depressed.             
 I feel very sad, melancholic or depressed.               
 I feel extremely sad, melancholic or depressed.             
Distress            
 I do not feel at all anxious, stressed or nervous.            
 I feel slightly anxious, stressed or nervous.             
 I feel moderately anxious, stressed or nervous.             
 I feel very anxious, stressed or nervous.             
 I feel extremely anxious, stressed or nervous.             
Vitality            
 I feel healthy and energetic.                      
 I feel slightly weary, tired or feeble.                       
 I feel moderately weary, tired or feeble.  
 I feel very weary, tired or feeble, almost exhausted.                       
 I feel extremely weary, tired or feeble, totally exhausted.  
Sexual Activity            
 My state of health has no adverse effect on my sexual activity. 
 My state of health has a slight effect on my sexual 
activity.  
           
 My state of health has a considerable effect on my sexual activity.  
 My state of health makes sexual activity almost 
impossible. 
           
 My state of health makes sexual activity impossible.            
 
  
Appendix 2: Disease-specific instruments applied 
DASS-21  
Please read each statement and circle a number 0, 1, 2 or 3 which indicates how much the statement 
applied to you over the past week. 
 
The rating scale is as follows:  
0 Did not apply to me at all  
1 Applied to me to some degree, or some of the time  
2 Applied to me to a considerable degree or a good part of time  
3 Applied to me very much or most of the time 
























4. I experienced breathing difficulty (eg, excessively rapid breathing, 


























































































































19. I was aware of the action of my heart in the absence of physical exertion (eg, 
















































































1. In the past 4 weeks, about how often did you feel tired 
for no good reason? 
                  
2. In the past 4 weeks, about how often did you feel 
nervous? 
                  
3. In the past 4 weeks, about how often did you feel so 
nervous that nothing could calm you down?                   
4. In the past 4 weeks, about how often did you feel 
hopeless?                   
5. In the past 4 weeks, about how often did you feel 
restless or fidgety?                   
6. In the past 4 weeks, about how often did you feel so 
restless that you could not sit still?                   
7. In the past 4 weeks, about how often did you feel 
depressed?                   
8. In the past 4 weeks, about how often did you feel that 
everything was an effort?                   
9. In the past 4 weeks, about how often did you feel so sad 
that nothing could cheer you up?                   
10. In the past 4 weeks, about how often did you feel 
worthless?                   
 
 
 
 
 
